Evercore ISI Maintains Buy Rating on Krystal Biotech with $200 Target

Krystal Biotech (KRYS) received a Buy rating from Evercore ISI with a $200.00 price target. The company's shares closed at $137.54. Gavin Clark-Gartner, a 4-star analyst, has an average return of 8.5% and a 52.56% success rate. Krystal Biotech also received a Buy from TR | OpenAI – 4o's Dex Genotek, but Citi maintained a Hold rating. The company's one-year high is $207.84, and its one-year low is $122.80.